LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

NASDAQ: LABT · HEALTHCARE · BIOTECHNOLOGY

$2.35

+5.86% today

Updated 2026-08-10

Market cap

$3.54M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$1 – $10

Volume

1.9M

Market cap

$3.54M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.26

Dividend yield

—

52W range

$1 – $10

Volume

1.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.3

Quality

C+

3.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →212 stocks currently score above 75

Price targets

Analyst target

$12.00

+410.64%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

+ Debt/equity -0.62x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-349691.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00
Net income	$-8.28M	$-4.86M	$-3.85M	$-923291.00
EPS	—	—	—	$-3.26
Free cash flow	$-6.82M	$-5.73M	$-1.94M	$-349691.00
Profit margin	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LABT	$3.54M	17	4.3	3.5	5.0	5.3	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$614.36B	57	4.7	8.5	3.3	6.0	-87.34%	Buy
ABBV	$430.82B	73	6.7	8.5	4.7	5.0	-64.01%	Strong Buy
UNH	$370.11B	62	7.3	5.5	4.0	6.0	-28.08%	Buy
MRK	$316.14B	50	3.3	8.0	2.7	5.0	-57.98%	Hold

Smart narrative

Lakewood-Amedex Biotherapeutics Inc. Common Stock trades at $2.35. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score.

Frequently asked questions

What is Lakewood-Amedex Biotherapeutics Inc. Common Stock's stock price?

Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT) trades at $2.35.

Is Lakewood-Amedex Biotherapeutics Inc. Common Stock overvalued?

Lakewood-Amedex Biotherapeutics Inc. Common Stock carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)?

The 12-month analyst consensus target is $12.00, about 410.6% above the current $2.35. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE—

Beta—

50D MA$4.45

200D MA$12.46

Shares out0.00B

Float0.00B

Short ratio—

Avg volume1.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LABT vs LLY →LABT vs JNJ →LABT vs ABBV →Stock screener →